Dr. Figlin on lessons from CANTATA study of telaglenastat/cabozantinib in mRCC

Video

Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, discusses results from the phase 2 CANTATA study of cabozantinib (Cabometyx) plus either the novel glutaminase inhibitor telaglenastat (CB-839) or placebo in patients with advanced/metastatic renal cell carcinoma (mRCC) who progressed on immune checkpoint inhibitors or antiangiogenic therapies. Results presented at the 2021 ASCO Annual Meeting showed that the addition of telaglenastat did not improve the efficacy of cabozantinib in mRCC. In the video, Figlin explains key lessons learned from the results.

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.